Rheumatoid arthritis and its animal models: The role of TNF-α and the possible absence of specific immune reactions

Current Opinion in Immunology

Volumn 11, Issue 6, 1999, Pages 657-662

  Klareskog, Lars ^a   McDevitt, Hugh ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Rm D ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; COLLAGEN TYPE 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADJUVANT ARTHRITIS; AUTOIMMUNITY; CARTILAGE CELL; GENETIC ANALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY DISEASE; LONG TERM CARE; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

EID: 0032706141     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00033-3     Document Type: Review

References (50)

1. Gergersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30:1987;1205-1213.
2. Thomson W., Harrisson B., Ollier B., Wiles N., Payton T., Barrett J., Symons D., Silman A. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis. Results from a large, population-based study. Arthritis Rheum. 42:1999;757-762. This carefully performed study demonstrates that the shared epitope (of HLA-DR) confers a relatively small risk for RA in a population-based patient group. The study provides further support for the view that the shared epitope is, to a large extent, a severity factor in RA.
3. van der Horst-Bruinsma I.E., Visser H., Hazes J.M., Breedveld F., Verduyn W., Schreuder G.M., de Vries R.R., Zanelli E. HLA-DQ-associated predisposion to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol. 60:1999;152-158.
4. Fugger L., Svejgaard A. The HLA-DQ7 and -DQ8 associations in DR4-positive rheumatoid arthritis patients. Tissue Antigens. 50:1997;494-500.
5. Kaijzel E.L., van Krugten M.V., Brinkman B.M., Huizinga T.W., van der Straaten T., Hazes J.M., Ziegler-Heitbrock H.W., Nedospasov S.A., Breedveld F.C., Verweij C.L. Functional analysis of a human tumor necrosis factor alpha promotor polymorphism related to joint damage in rheumatoid arthritis. Mol Med. 4:1998;724-733.
6. Mu H., Chen J.J., Jiang Y., King M.C., Thomson G., Criswell L. Tumor necrosis factor α microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. Arthritis Rheum. 42:1999;438-442.
7. Cantagrel A., Navaux F., Loubet-Lescoulié P., Nourhashemi F., Anault G., Abbal M., Constantin A., Larouche M., Mazieres B. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms. Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 42:1999;1101-1108.
8. Becker K.G., Simon R.M., Bailey-Wilson J.E., Freidlin B., Biddison W.E., McFarland H.F., Trent J.M. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA. 95:1998;9979-9984.
9. Silman A.J., MacGregor A.J., Thomson W., Holligan S., Carthy D., Farhan A., Ollier W.E.R., Silman A.J. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol. 32:1993;903-907.
10. Symmons D.P.M., Bankhead C.R., Harrisson B.J., Brennan P., Barrett E.M., Scott D.G.I., Silman A.J. Blood transfusion, smoking and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 40:1997;1955-1961.
11. Karlson E.W., Lee I.-M., Cook N., Manson J., Buring J., Hennekens C. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 42:1999;910-917.
12. Bläss S., Schuman F., Hain N., Engel J.M., Stuhlmuller B., Burmester G.R. p205 is a major target of autoreactive T cells in rheumatoid arthritis. Arthritis Rheum. 42:1999;971-980. A new and interesting candidate autoantigen in RA is identified.
13. Guerassimov A., Zhang Y., Banerjee S., Cartman A., Leroux J.-Y., Rosenberg L.C., Esdaile J., Fitzcharles M.-A., Poole A.R. Cellular immunity to the G1 domain of cartilage proteoglycan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulphate. Arthritis Rheum. 41:1998;1019-1025. Previous studies on proteoglycans as candidate autoantigens in RA are extended and a potential cryptic epitope is identified.
14. Verheijden G.F., Rijnders A.W., Bos E., Cooenen-de Roo C.J., van Staveren C.J., Miltenburg A.M., Meijerink J.H., Elewaut D., de Keyser F., Veys E., Boots A.M. Human cartilage glycoproteion-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 40:1997;1115-1125.
15. Berg L., Rönnelid J., Sanjeevi C.B., Lampa J., Klareskog L. T-cell reactivity to collagen type II in rheumatoid arthritis is associated with HLA-DR4 and HLA-DQ8. Arthritis Research. 1999;. in press.
16. Smeets T.J., Dolhain R., Miltenburg A.M., de Kuiper R., Breedveld F.C., Tak P.P. Poor expression of T-cell-derived cytokine and proliferation markers in early rheumatoid synovial tissue. Clin Immunol Immunopathol. 88:1998;84-90.
17. Tak P.P., Smeets J.M., Boyle D., Kraan M.C., Shi Y., Shuamg S., Zvaifler N.J., Breedveld F.C., Firestein G.S. p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum. 42:1999;948-953. The hypothesis of a role for p53-dependent growth stimulation in the synovium is extended with new interesting information.
18. Maurice M.M., Lankester A.C., Bezemer A.C., Geertsma M.F., Tak P.P., Breedveld F.C., Lier R.A.W., Verweij C.L. Defective TCR-mediated signalling in synovial T cells in rheumatoid arthritis. J Immunol. 159:1997;2973-2978.
19. Matsuda M., Ulfgren A.-K., Lenkei R., Petersson M., Ochoa A.C., Lindblad S., Andersson P., Klareskog L., Kiessling R. Decreased expression of signal transducing CD3ζ chains in T cell from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol. 47:1998;254-262.
20. Cope A.P., Liblau R.S., Yang X.D., Congia M., Laudanna C., Schreiber R.D., Probert L., Kollias G., McDevitt H.O. Chronic tumor necrosis factor exposure alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 185:1997;1573-1584.
21. Cope A.P., Londei M., Randall-Chu N., Cohen S.B.A., Eliott M.J., Brennan F.M., Maini R.N., Feldmann M. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 94:1994;749-760.
22. Cremer M.A., Ye X.J., Terato K., Griffiths M.M., Watson W.C., Kang A.H. Immunity to type IX collagen in rodents: a study of type IX collagen for autoimmune and arthritogenic activities. Clin Exp Immunol. 112:1998;375-382.
23. Carlsen S., Hansson A.S., Olsson H., Heinegård D., Holmdahl R. Cartilage oligomeric matrix protein (COMP) induced arthritis in rats. Clin Exp Immunol. 114:1998;477-484. A new cartilage-derived candidate autoantigen for arthritis is defined.
24. Glant T., Cs-Szabo G., Nagase H., Jacobs J.J., Mikecz K. Progressive polyarthritis induced in Balb/c mice by aggrecan from normal and osteoarthritis human cartilage. Arthritis Rheum. 41:1998;1007-1018. Further evidence is presented that aggrecan is a candidate autoantigen in arthritis.
25. Zhang Y., Guerassimov A., Leroux J.-Y., Cartman A., Webber C., Lalic R., Miguel E., Rosenberg L., Poole A.R. Induction of arthritis in Balb/c mice by cartilage link protein. Am J Pathol. 153:1998;1283-1291. Further evidence is presented that cartilage link protein is a candidate autoantigen in arthritis.
26. Malmström V., Kjellen P., Holmdahl R. Type II collagen in cartilage evokes peptide-specific tolerance and skews the immune response. J Autoimm. 11:1998;213-221. Interesting new data are presented on potential mechanisms behind the partial anergy previously observed in T cells reactive with the immunodominant epitope of self collagen type II.
27. Corthay A., Bäcklund J., Broddefalk J., Michaelsson E., Goldschmidt T., Kihlberg J., Holmdahl R. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol. 28:1998;2580-2590. The study demonstrates that T cells recognizing glycosylated epitopes of collagen II can be critical for the induction of collagen-induced arthritis.
28. Lorentzen J.C., Glaser A., Jacobsson L., Galli J., Fakhrai-Rad H., Klareskog L., Luthman H. Identification of rat susceptibility loci for adjuvant-oil-induced arthritis. Proc Natl Acad Sci USA. 95:1998;6383-6387.
29. Jirholt J., Cook A., Emahazion T., Sundvall M., Jansson L., Nordquist N., Pettersson U., Holmdahl R. Genetic linkage analysis of collagen-induced arthritis in the mouse. Eur J Immunol 28:3321-3328. 1998.
30. McIndoe R.A., Bohlman B., Chi E., Schuster E., Lindhardt M., Hood L. Localization of non-MHC collagen-induced arthritis susceptibility loci in DBA/1j mice. Proc Natl Acad Sci USA. 96:1999;2210-2214.
31. Gulko P., Kawahito Y., Remmers E., Reese R., Wang J., Dracheva S., Lynn G., Longman R., Shepard J., Cannon G.et al. Identification of a new non-major histocompatibility complex genetic locus on chromosome 2 that controls disease severity in collagen-induced arthritis in rats. Arthritis Rheum. 41:1999;2122-2131.
32. Kleinau S., Erlandsson H., Holmdahl R., Klareskog L. Adjuvant oils induce arthritis in the DA rat. 1. Characterization of the disease and evidence for an immunological inolvement. J Autoimmunity. 4:1991;871-880.
33. Lorentzen J.C. Identification of arthritogenic adjuvants of self and foreign origin. Scand J Immunol. 49:1999;45-50.
34. Wooley P.H., Sud S., Whalen J.D., Nasser S. Pristane-induced arthritis in mice. V. Susceptibility to pristane-induced arthritis is determined by the genetic regulation of the T cell repertoire. Arthritis Rheum. 41:1998;2022-2031.
35. Yoshino S., Murata Y., Ohsawa M. Successful induction of adjuvant arthritis in mice by treatment with a monoclonal antibody against Il-4. J Immunol. 161:1998;6904-6908.
36. Holmdahl R. Genetics of susceptibility to chronic experimental encephalomyelitis and arthritis. Curr Opin Immunol. 10:1998;710-717.
37. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumor necrosis factor: a predictive model of arthritis. EMBO J. 10:1991;4025-4031.
38. Butler D.M., Malfait A.M., Mason L.J., Warden P.J., Kollias G., Maini R.N., Feldmann M., Brennan F.M. DBA/1 mice expressing the human TNF-α transgene develop a severe erosive arthritis. J Immunol. 159:1997;2867-2876.
39. Plows D., Kontogeorgos G., Kollias G. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol. 162:1999;1018-1023. An original and surprising report showing that collagen immunization may cause arthritis in mice lacking functional T and B lymphocytes.
40. Kouskoff V., Korganow A.-S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:1996;811-822.
41. Korganow A.-S., Ji H., Mangialaio S., Duchtelle V., Pelanda R., Martin T., Degott C., Kikutani H., Rajewsky K., Pasquali J.L.et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 10:1999;451-461. A conceptually very important study which demonstrates immunoglobulins to be responsible for induction of arthritis in animals in which T cell activation against a ubiquitous and systemically exposed autoantigen has previously taken place.
42. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., MacFarlade J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N.et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563. A very important clinical study on the effects of an anti-TNF-α monoclonal antibody in RA patients who have active disease despite methotrexate therapy.
43. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:1999;253-259. A very important study demonstrating effects of TNF-α-blockade - using the recombinant p75 TNF receptor - in RA patients who have active disease despite methotrexate therapy.
44. Ulfren A.-K., Andersson U., Engström M., Klareskog L., Maini R.N., Taylor P.C. Systemic anti-TNFα therapy in rheumatoid arthritis down-regulates synovial TNFα formation [abstract]. Arthritis Rheum. 1999;405in press.
45. Brennan F.M., Maini R.N., Feldmann M. TNFα: a pivotal role in rheumatoid arthritis. Br J Rheumatol. 31:1992;293-298.
46. Pasparakis M., Alexopolou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNFα-deficient mice. A critical requirement of TNFα in the formation of B cell follicular dendritic cell network and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 184:1996;1397-1411.
47. Jacob C.O., McDevitt H.O. Tumor necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature. 331:1988;356-357.
48. Jacob C.O., Aiso S., Michie S.A., McDevitt H.O., Acha-Orbea H. Prevention of diabetes in non-obese diabetic mice by tumor necrosis factor (TNF): similarities between TNFα and interleukin 1. Proc Natl Acad Sci USA. 87:1990;968-972.
49. Ishida H., Muchamvel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 179:1994;305-310.
50. Yang S.D., Tisch R., Singer S.M., Cao Z.A., Liblau R.S., Schreiber R.S., McDevitt H.O. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 180:1994;995-1004.